A digital lifestyle program was linked to lasting improvements in several measures reported by multiple sclerosis patients, a study says.

New research and input from people living with MS are changing how the disease is diagnosed and treated — a shift that will ...

WEST PALM BEACH, Fla. — Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) after prolonged disease stability poses minimal risk for patients aged > 60 years, highlighting the ...

Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system ...

A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite ...

Multiple Sclerosis (MS) imposes a significant psychological burden that adversely affects patients’ subjective well-being (SWB). A primary psychological stressor in this population is the Fear of ...

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed ...

Registry-linked gross income trajectories (wages, capital gains, transfers) showed lower long-term income growth in 1,071 MS cases versus 15,493 matched controls, with 72% women in the cohort.

For decades, the common medical shorthand has been that if you have a young-to-middle-age white female patient of northern European ancestry with neurological symptoms, you should immediately suspect ...

A collaborative investigation among experts in Alzheimer's disease and multiple sclerosis (MS) finds evidence that MS patients are less likely to have amyloid plaques, a hallmark of Alzheimer's ...

The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS). This ...